Magnus Hansson, MD, PhD • Chair

Dr. Hansson accepted the position of co-chair to the UMDF’s Industry Advisory Council (IAC) in 2025.

Magnus is Executive Medical Director and KL1333 Global Program Team Lead for Abliva, A Member of Pharming Group. He received his Medical Degree in 2002 and PhD in 2007 from Lund University, Sweden, where he holds an Associate Professorship. He served as a specialist physician in clinical physiology prior to joining Abliva in 2016. At Abliva, he headed the development of a portfolio of innovative compounds for mitochondrial disease including KL1333 which is currently in a pivotal stage clinical trial, the FALCON study. Abliva was acquired by the rare disease company Pharming in 2025, where Magnus now leads the global program for KL1333. Magnus has a long-standing commitment to mitochondrial medicine development authoring 60+ scientific publications and 10+ patent families.